Kevin D. Bunker is Chief Scientific Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 834,931 shares of ZNTL, which is worth approximately $2.66 Million. The most recent transaction as insider was on Dec 20, 2023, when has been sold 24,158 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 835K
0% 3M change
0% 12M change
Total Value Held $2.66 Million

Kevin D. Bunker Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 20 2023
SELL
Bona fide gift
-
24,158 Reduced 2.81%
834,931 Common Stock
Oct 04 2023
SELL
Open market or private sale
$119,357 $19.67 p/Share
6,068 Reduced 0.7%
859,089 Common Stock
Feb 14 2023
SELL
Open market or private sale
$129,870 $19.98 p/Share
6,500 Reduced 0.75%
865,157 Common Stock
Feb 13 2023
SELL
Open market or private sale
$77,738 $20.42 p/Share
3,807 Reduced 0.43%
871,657 Common Stock
Feb 01 2023
BUY
Grant, award, or other acquisition
-
91,354 Added 9.45%
875,464 Common Stock
Nov 09 2022
SELL
Bona fide gift
-
30,000 Reduced 3.69%
784,110 Common Stock
Oct 03 2022
BUY
Grant, award, or other acquisition
-
50,000 Added 5.79%
814,110 Common Stock
Feb 14 2022
SELL
Open market or private sale
$236,275 $50.4 p/Share
4,688 Reduced 0.61%
764,110 Common Stock
Feb 10 2022
BUY
Grant, award, or other acquisition
-
22,481 Added 2.84%
768,798 Common Stock
Dec 30 2021
SELL
Bona fide gift
-
8,750 Reduced 1.16%
746,317 Common Stock
Nov 09 2021
SELL
Bona fide gift
-
240,000 Reduced 24.12%
755,067 Common Stock
Sep 24 2021
SELL
Bona fide gift
-
350 Reduced 0.04%
995,067 Common Stock
Jul 07 2021
SELL
Open market or private sale
$212,339 $47.04 p/Share
4,514 Reduced 0.45%
1,008,788 Common Stock
Jul 06 2021
SELL
Open market or private sale
$968,012 $47.69 p/Share
20,298 Reduced 2.0%
994,841 Common Stock
Apr 06 2021
SELL
Open market or private sale
$11,896 $43.26 p/Share
275 Reduced 0.03%
1,019,653 Common Stock
Apr 05 2021
SELL
Open market or private sale
$1,079,584 $44.0 p/Share
24,536 Reduced 2.35%
1,019,928 Common Stock
Feb 11 2021
BUY
Grant, award, or other acquisition
-
18,750 Added 1.76%
1,044,464 Common Stock
Jan 04 2021
SELL
Open market or private sale
$1,376,436 $51.81 p/Share
26,567 Reduced 2.52%
1,025,713 Common Stock
Dec 24 2020
SELL
Bona fide gift
-
1,600 Reduced 0.15%
1,052,280 Common Stock
Dec 07 2020
SELL
Open market or private sale
$575,860 $52.87 p/Share
10,892 Reduced 1.02%
1,053,880 Common Stock
Dec 04 2020
SELL
Open market or private sale
$619,928 $50.96 p/Share
12,165 Reduced 1.13%
1,064,772 Common Stock
Nov 23 2020
SELL
Bona fide gift
-
101,045 Reduced 8.58%
1,076,937 Common Stock
Apr 07 2020
BUY
Open market or private purchase
$6,300 $18.0 p/Share
350 Added 0.03%
1,177,982 Common Stock
KDB

Kevin D. Bunker

Chief Scientific Officer
New York, NY

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL